XTL Biopharmaceuticals (XTLB) received a letter from Nasdaq for not complying with its listing rules after failing to file its 2025 Form 20-F annual report, the company said late Friday.
The company is also facing a Nasdaq Hearings Panel review for not meeting the minimum $2.5 million stockholders' equity and $1 bid price listing requirements.
These issues could lead to a potential delisting, and the company has until May 26 to request a stay of the suspension of its securities, it said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.